Jami Rubin

TEVA Pharmaceutical Industries (NASDAQ: TEVA)'s fundamentals have substantially improved over the last few months, giving the stock a more balanced risk-reward profile, according to Leerink.  The Analyst Leerink analyst Ami Fadia upgraded TEVA Pharmaceutical from Underperform to Market...

The iShares Dow Jones US Healthcare (ETF) (NYSE: IYH) is up marginally year-to-date, but the profits aren’t bleeding into all health care constituents. The Ratings Goldman Sachs analyst Jami Rubin upgraded Johnson & Johnson (NYSE: JNJ) from Sell to Neutral and maintained a $134 price...

The Merck & Co., Inc. (NYSE: MRK) story has slowly captivated analysts, and on Monday the pharmaceutical company corralled Goldman Sachs in its growing bullpen.  The Rating Analyst Jami Rubin upgraded Merck from Neutral to Buy and increased the price target from $63 to $73. The Thesis...

The case for buying shares of Eli Lilly and Co (NYSE: LLY) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes franchise, according to Goldman Sachs.  The Analyst Goldman Sachs' Jami Rubin...

Teva Pharmaceutical Industries Ltd (ADR) (NYSE: TEVA) announced Thursday a plan to eliminate more than 25 percent of its worldwide workforce as part of a strategy to slash $3 billion of annual costs. The Analyst Goldman Sachs' Jami Rubin upgraded Teva's stock from Neutral to Buy with...

Analysts at Goldman Sachs turned bearish on industry giant Johnson & Johnson (NYSE: JNJ) amid valuation concerns. Analyst Jami Rubin downgraded J&J's stock from Neutral to Sell with a price target boosted from $125 to $130, which implies downside from Wednesday's open of $133.25....

A day after Eli Lilly and Co (NYSE: LLY) reported earnings and sales misses for the third quarter, Goldman Sachs reduced its revenue and EPS estimate by 1–3 percent for 2016–2025 based on the conservative expectations of Jardiance, Humalog and Portrazza. However, the firm thinks that...

This year’s European Society for Medical Oncology conference was one that Bristol-Myers Squibb Co (NYSE: BMY) shareholders would like to forget. The primary focus for Bristol-Myers was the company’s failed CM-26 trial. Bristol-Myers shares are down 9.4 percent in early Monday...

“Political pressure on drug pricing has reached the point where the ability of biopharma companies to adapt to a more restrained pricing environment will differentiate winners and losers, in our view,” Goldman Sachs’ Jami Rubin said in a report. The industry would need to adopt...

Eli Lilly and Co (NYSE: LLY) seems to be entering “a long lasting period of accelerating revenue and EPS growth driven by a diversified late stage pipeline propelling many years of margin expansion,” Goldman Sachs’ Jami Rubin said in a report. He upgraded the rating on the...

Goldman Sachs’ Jami Rubin believes AbbVie Inc (NYSE: ABBV) is one of the most “dislocated names” in the pharmaceutical space, with its below peer valuation not reflective of the company’s above industry growth outlook and broad pipeline. Rubin maintained a Buy rating on...

Mylan NV (NASDAQ: MYL)'s announcement that it will offer patient assistance via a coupon that could effectively slash the price of its EpiPen drug by 50 percent should "quell" investor concern, at least according to Goldman Sachs' Jami Rubin. Rubin commented in a report that...

Pfizer Inc. (NYSE: PFE) finalized a deal to acquire Medivation Inc (NASDAQ: MDVN) for $14 billion Monday morning. Goldman Sachs’ Jami Rubin has a 12-month price target of $37 for Pfizer. Rubin stated that the acquisition would be consistent with Pfizer’s “stated interest in...

Goldman Sachs said evidence of Merck & Co., Inc. (NYSE: MRK)'s Keytruda benefit as a single agent continues to build as registrational monotherapy studies read out. Merck's data presented at ASCO (American Society of Clinical Oncology) include updates on new tumors, existing tumors and...